Lack of CD8 <sup>+</sup> T cell effector differentiation during priming mediates checkpoint blockade resistance in non–small cell lung cancer

Brendan Horton(Allen Institute), Stefani Spranger(Massachusetts Institute of Technology)

Science Immunology

October 29, 2021

10.1126/sciimmunol.abi8800

Cited by 127

Related Papers

Impact of oncogenic pathways on evasion of antitumour immune responses

|Nature reviews. Cancer|2018|652

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

|Journal for ImmunoTherapy of Cancer|2014|543

Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer

|Immunity|2023|145